Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Mesoblast Ltd (ADR) - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MESO
Nasdaq
8731
https://www.mesoblast.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Mesoblast Ltd (ADR)
Mesoblast (MESO) to File Pediatric GVHD Drug BLA, Stock Up
- Mar 27th, 2024 3:00 pm
After Almost 4 Years, FDA Says Mesoblast Phase 3 Therapy Data Can Support Resubmission For Serious Complications in Children Following Stem Cell Transplant
- Mar 26th, 2024 6:47 pm
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
- Mar 26th, 2024 2:34 am
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
- Mar 13th, 2024 11:30 pm
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
- Mar 10th, 2024 11:54 pm
Mesoblast Limited (NASDAQ:MESO) Q2 2024 Earnings Call Transcript
- Mar 3rd, 2024 1:25 pm
Mesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues Lag
- Feb 29th, 2024 8:41 pm
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
- Feb 28th, 2024 10:57 pm
Mesoblast Financial Results and Corporate Update Webcast
- Feb 26th, 2024 12:00 pm
United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
- Feb 15th, 2024 12:46 am
Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
- Jan 31st, 2024 2:13 am
Mesoblast (MESO) Up on Rare Pediatric Disease Tag for Heart Drug
- Jan 19th, 2024 4:30 pm
United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
- Jan 18th, 2024 11:36 pm
Mesoblast (ASX:MSB) investors are sitting on a loss of 88% if they invested three years ago
- Jan 9th, 2024 12:35 am
Mesoblast Limited (MESO) Loses -5.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Jan 5th, 2024 2:35 pm
5 Stocks to Ride the Santa Claus Rally
- Dec 21st, 2023 2:38 pm
Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
- Nov 26th, 2023 11:56 pm
Mesoblast (MESO) Up on Deal With BMT CTN to Develop GVHD Drug
- Nov 23rd, 2023 2:27 pm
Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
- Nov 21st, 2023 11:32 pm
Most Shareholders Will Probably Find That The Compensation For Mesoblast Limited's (ASX:MSB) CEO Is Reasonable
- Nov 21st, 2023 4:57 am
Scroll